Header Logo

Connection

JORGE E CORTES to Drug Resistance, Neoplasm

Back to Details
This is a "connection" page, showing publications JORGE E CORTES has written about Drug Resistance, Neoplasm.
JORGE E CORTES
Connection Strength
6.719
Drug Resistance, Neoplasm
  1. Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy. Eur J Haematol. 2021 Jun; 106(6):808-820.
    View in: PubMed
    Score: 0.279
  2. Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib. Blood Cancer J. 2018 09 03; 8(9):88.
    View in: PubMed
    Score: 0.234
  3. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018 07 26; 132(4):393-404.
    View in: PubMed
    Score: 0.227
  4. The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia. Haematologica. 2013 Oct; 98(10):e131.
    View in: PubMed
    Score: 0.166
  5. Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors. Haematologica. 2013 Jul; 98(7):e78-9.
    View in: PubMed
    Score: 0.163
  6. Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood. 2012 Oct 18; 120(16):3382-3.
    View in: PubMed
    Score: 0.156
  7. Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure. J Natl Compr Canc Netw. 2012 Oct 01; 10 Suppl 3:S1-S13.
    View in: PubMed
    Score: 0.155
  8. Clinical roundtable monograph: Emerging treatment options for TKI-resistant chronic myelogenous leukemia. Clin Adv Hematol Oncol. 2012 Oct; 10(10 Suppl 19):1-16.
    View in: PubMed
    Score: 0.155
  9. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood. 2012 Sep 27; 120(13):2573-80.
    View in: PubMed
    Score: 0.154
  10. Chronic myeloid leukemia: mechanisms of resistance and treatment. Hematol Oncol Clin North Am. 2011 Oct; 25(5):981-95, v.
    View in: PubMed
    Score: 0.145
  11. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011 Oct 27; 118(17):4567-76.
    View in: PubMed
    Score: 0.144
  12. Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. Blood. 2011 May 26; 117(21):5600-6.
    View in: PubMed
    Score: 0.140
  13. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood. 2009 Sep 03; 114(10):2037-43.
    View in: PubMed
    Score: 0.124
  14. Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia. Am J Hematol. 2009 Apr; 84(4):256-7.
    View in: PubMed
    Score: 0.122
  15. Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure. Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S272-9.
    View in: PubMed
    Score: 0.120
  16. The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer. 2008 Sep 15; 113(6):1338-43.
    View in: PubMed
    Score: 0.117
  17. Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin Cancer Res. 2008 Jul 15; 14(14):4392-9.
    View in: PubMed
    Score: 0.116
  18. Management of patients with resistant or refractory chronic myelogenous leukemia. Oncology (Williston Park). 2008 Apr 15; 22(4):430-7; discussion 437, 442, 446 passim.
    View in: PubMed
    Score: 0.114
  19. Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia. J Natl Compr Canc Netw. 2008 Mar; 6 Suppl 2:S22-S30.
    View in: PubMed
    Score: 0.113
  20. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood. 2007 Dec 01; 110(12):4005-11.
    View in: PubMed
    Score: 0.109
  21. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer. 2007 Apr 15; 109(8):1556-60.
    View in: PubMed
    Score: 0.106
  22. Overcoming drug resistance in chronic myeloid leukemia. Curr Opin Hematol. 2006 Mar; 13(2):79-86.
    View in: PubMed
    Score: 0.098
  23. Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia. Expert Rev Hematol. 2024 Jun; 17(6):211-221.
    View in: PubMed
    Score: 0.087
  24. Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after =1 prior tyrosine kinase inhibitor: 2-year follow-up results. Leukemia. 2024 Jul; 38(7):1522-1533.
    View in: PubMed
    Score: 0.087
  25. Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial. Future Oncol. 2022 Dec; 18(38):4161-4170.
    View in: PubMed
    Score: 0.079
  26. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood. 2003 Jan 15; 101(2):473-5.
    View in: PubMed
    Score: 0.077
  27. Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome?positive leukemias. Leuk Res. 2021 12; 111:106690.
    View in: PubMed
    Score: 0.072
  28. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov. 2021 03; 2(2):125-134.
    View in: PubMed
    Score: 0.068
  29. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discov. 2019 03; 9(3):370-383.
    View in: PubMed
    Score: 0.059
  30. Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. Am J Hematol. 2019 01; 94(1):46-54.
    View in: PubMed
    Score: 0.059
  31. Treatment of Relapsed/Refractory Acute Myeloid Leukemia. Curr Treat Options Oncol. 2017 03; 18(3):17.
    View in: PubMed
    Score: 0.053
  32. Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. Haematologica. 2017 03; 102(3):519-528.
    View in: PubMed
    Score: 0.052
  33. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood. 2016 Feb 11; 127(6):703-12.
    View in: PubMed
    Score: 0.048
  34. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib. Br J Haematol. 2016 Jan; 172(1):97-110.
    View in: PubMed
    Score: 0.048
  35. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. Br J Haematol. 2015 Nov; 171(4):471-7.
    View in: PubMed
    Score: 0.047
  36. Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival. Clin Lymphoma Myeloma Leuk. 2015 Sep; 15(9):556-62.
    View in: PubMed
    Score: 0.047
  37. Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up. Cancer. 2015 May 15; 121(10):1637-44.
    View in: PubMed
    Score: 0.045
  38. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014 Sep 08; 26(3):428-442.
    View in: PubMed
    Score: 0.044
  39. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies. Clin Cancer Res. 2014 May 01; 20(9):2363-74.
    View in: PubMed
    Score: 0.043
  40. Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia. Clin Cancer Res. 2014 Apr 01; 20(7):1735-40.
    View in: PubMed
    Score: 0.043
  41. Tosedostat for the treatment of relapsed and refractory acute myeloid leukemia. Expert Opin Investig Drugs. 2014 Feb; 23(2):265-72.
    View in: PubMed
    Score: 0.042
  42. Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):515-29.
    View in: PubMed
    Score: 0.041
  43. KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors. Cancer Res. 2013 Sep 15; 73(18):5775-86.
    View in: PubMed
    Score: 0.041
  44. Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):477-84.
    View in: PubMed
    Score: 0.041
  45. Chronic myeloid leukemia: overview of new agents and comparative analysis. Curr Treat Options Oncol. 2013 Jun; 14(2):127-43.
    View in: PubMed
    Score: 0.041
  46. Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors. Am J Hematol. 2013 May; 88(5):350-4.
    View in: PubMed
    Score: 0.040
  47. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012 Nov 29; 367(22):2075-88.
    View in: PubMed
    Score: 0.039
  48. Dasatinib for the treatment of Philadelphia chromosome-positive leukemias. Expert Opin Pharmacother. 2012 Nov; 13(16):2381-95.
    View in: PubMed
    Score: 0.039
  49. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 2013 Jan; 27(1):107-12.
    View in: PubMed
    Score: 0.038
  50. Molecular resistance: an early indicator for treatment change? Clin Lymphoma Myeloma Leuk. 2012 Apr; 12(2):79-87.
    View in: PubMed
    Score: 0.037
  51. Chronic myeloid leukemia: the race is yet to be won. CMAJ. 2012 May 15; 184(8):857-8.
    View in: PubMed
    Score: 0.037
  52. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia. 2012 Jun; 26(6):1189-94.
    View in: PubMed
    Score: 0.036
  53. Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia. PLoS One. 2011; 6(7):e22110.
    View in: PubMed
    Score: 0.036
  54. The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm. Cancer. 2012 Jan 15; 118(2):293-9.
    View in: PubMed
    Score: 0.036
  55. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood. 2011 Mar 31; 117(13):3641-7.
    View in: PubMed
    Score: 0.034
  56. Proceedings of the Third Global Workshop on Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2010 Dec; 10(6):443-51.
    View in: PubMed
    Score: 0.034
  57. Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. Blood. 2010 Dec 23; 116(26):5818-23; quiz 6153.
    View in: PubMed
    Score: 0.034
  58. Towards a cure for chronic myeloid leukemia: are we there yet? Semin Hematol. 2010 Oct; 47(4):299-301.
    View in: PubMed
    Score: 0.034
  59. Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one? Semin Hematol. 2010 Oct; 47(4):344-53.
    View in: PubMed
    Score: 0.034
  60. Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects. Blood. 2010 Jul 01; 115(26):5428-9.
    View in: PubMed
    Score: 0.033
  61. Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer. 2010 Jun 01; 116(11):2673-81.
    View in: PubMed
    Score: 0.033
  62. Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Cancer. 2009 Jul 01; 115(13):2912-21.
    View in: PubMed
    Score: 0.031
  63. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol. 2009 Aug 01; 27(22):3642-9.
    View in: PubMed
    Score: 0.031
  64. Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells. J Cell Mol Med. 2010 Jun; 14(6B):1777-92.
    View in: PubMed
    Score: 0.031
  65. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control. 2009 Apr; 16(2):122-31.
    View in: PubMed
    Score: 0.030
  66. Optimizing first-line therapy for patients with chronic myeloid leukemia. Semin Hematol. 2009 Apr; 46(2 Suppl 3):S5-10.
    View in: PubMed
    Score: 0.030
  67. BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors. Acta Haematol. 2009; 121(1):27-31.
    View in: PubMed
    Score: 0.030
  68. Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy? Mayo Clin Proc. 2009 02; 84(2):161-9.
    View in: PubMed
    Score: 0.030
  69. Treatment selection after imatinib resistance in chronic myeloid leukemia. Target Oncol. 2009 Jan; 4(1):3-10.
    View in: PubMed
    Score: 0.030
  70. Standard management of patients with chronic myeloid leukemia. Clin Lymphoma Myeloma. 2009; 9 Suppl 4:S382-90.
    View in: PubMed
    Score: 0.030
  71. BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations. Mol Cancer Ther. 2008 Dec; 7(12):3834-41.
    View in: PubMed
    Score: 0.030
  72. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia. 2008 Dec; 22(12):2176-83.
    View in: PubMed
    Score: 0.029
  73. Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations. Cancer. 2008 Apr 15; 112(8):1744-53.
    View in: PubMed
    Score: 0.028
  74. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood. 2008 Jul 01; 112(1):53-5.
    View in: PubMed
    Score: 0.028
  75. BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices. J Natl Compr Canc Netw. 2008 Mar; 6 Suppl 2:S37-42; quiz S43-S44.
    View in: PubMed
    Score: 0.028
  76. Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia. Clin Lymphoma Myeloma. 2008 Mar; 8 Suppl 3:S82-8.
    View in: PubMed
    Score: 0.028
  77. Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones. Leuk Res. 2008 Aug; 32(8):1313-6.
    View in: PubMed
    Score: 0.028
  78. Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure. Cancer. 2007 Nov 01; 110(9):2000-6.
    View in: PubMed
    Score: 0.028
  79. Nilotinib therapy in chronic myelogenous leukemia. Drugs Today (Barc). 2007 Oct; 43(10):691-702.
    View in: PubMed
    Score: 0.027
  80. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy. Leuk Res. 2008 Apr; 32(4):643-9.
    View in: PubMed
    Score: 0.027
  81. Farnesyl transferase inhibitor resistance probed by target mutagenesis. Blood. 2007 Sep 15; 110(6):2102-9.
    View in: PubMed
    Score: 0.027
  82. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007 Apr 15; 109(8):3207-13.
    View in: PubMed
    Score: 0.026
  83. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med. 2006 Dec 19; 145(12):913-23.
    View in: PubMed
    Score: 0.026
  84. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood. 2007 Jan 15; 109(2):497-9.
    View in: PubMed
    Score: 0.026
  85. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia. 2006 Oct; 20(10):1767-73.
    View in: PubMed
    Score: 0.025
  86. Kinase inhibitors in chronic myelogenous leukemia. Clin Adv Hematol Oncol. 2006 May; 4(5):365-74.
    View in: PubMed
    Score: 0.025
  87. New strategies in chronic myeloid leukemia. Int J Hematol. 2006 May; 83(4):289-93.
    View in: PubMed
    Score: 0.025
  88. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood. 2006 Aug 15; 108(4):1421-3.
    View in: PubMed
    Score: 0.025
  89. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer. 2006 Jan 15; 106(2):346-52.
    View in: PubMed
    Score: 0.024
  90. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol. 2005 Jun 10; 23(17):3948-56.
    View in: PubMed
    Score: 0.023
  91. Imatinib mesylate in the treatment of chronic myelogenous leukemia. Int J Hematol. 2004 Jun; 79(5):411-9.
    View in: PubMed
    Score: 0.022
  92. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. Leuk Res. 2003 Dec; 27(12):1091-6.
    View in: PubMed
    Score: 0.021
  93. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. Haematologica. 2003 Aug; 88(8):853-63.
    View in: PubMed
    Score: 0.021
  94. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience. Cancer. 2003 May 01; 97(9):2218-24.
    View in: PubMed
    Score: 0.020
  95. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results. Leukemia. 2023 05; 37(5):1048-1059.
    View in: PubMed
    Score: 0.020
  96. BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study. Cancer. 2021 04 15; 127(8):1246-1259.
    View in: PubMed
    Score: 0.017
  97. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med. 2019 12 12; 381(24):2315-2326.
    View in: PubMed
    Score: 0.016
  98. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med. 2019 10 31; 381(18):1728-1740.
    View in: PubMed
    Score: 0.016
  99. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2018 07 01; 124(13):2758-2765.
    View in: PubMed
    Score: 0.014
  100. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. Cancer. 2018 06 15; 124(12):2534-2540.
    View in: PubMed
    Score: 0.014
  101. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2018 04; 59(4):813-820.
    View in: PubMed
    Score: 0.014
  102. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. Am J Hematol. 2017 06; 92(6):E114-E117.
    View in: PubMed
    Score: 0.013
  103. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol. 2016 09; 91(9):869-74.
    View in: PubMed
    Score: 0.013
  104. Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. Blood. 2015 Jul 09; 126(2):222-32.
    View in: PubMed
    Score: 0.012
  105. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol. 2015 Sep; 90(9):755-68.
    View in: PubMed
    Score: 0.012
  106. The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert Rev Anticancer Ther. 2015 Apr; 15(4):365-73.
    View in: PubMed
    Score: 0.011
  107. SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia. Br J Haematol. 2014 Sep; 166(6):862-74.
    View in: PubMed
    Score: 0.011
  108. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. Am J Hematol. 2014 Jul; 89(7):732-42.
    View in: PubMed
    Score: 0.011
  109. Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia. Expert Opin Investig Drugs. 2014 Jul; 23(7):943-54.
    View in: PubMed
    Score: 0.011
  110. Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy. Am J Hematol. 2014 Apr; 89(4):395-8.
    View in: PubMed
    Score: 0.011
  111. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood. 2014 Apr 10; 123(15):2317-24.
    View in: PubMed
    Score: 0.011
  112. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood. 2014 Feb 27; 123(9):1309-18.
    View in: PubMed
    Score: 0.011
  113. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014 Mar; 4(3):362-75.
    View in: PubMed
    Score: 0.011
  114. Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia. Expert Rev Anticancer Ther. 2013 Dec; 13(12):1433-52.
    View in: PubMed
    Score: 0.011
  115. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest. 2013 Oct; 123(10):4144-57.
    View in: PubMed
    Score: 0.010
  116. The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica. 2013 Oct; 98(10):1510-6.
    View in: PubMed
    Score: 0.010
  117. Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia. 2013 Apr; 27(4):907-13.
    View in: PubMed
    Score: 0.010
  118. Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. Blood. 2012 Jul 05; 120(1):173-80.
    View in: PubMed
    Score: 0.009
  119. Tyrosine kinase inhibitors in acute and chronic leukemias. Expert Opin Pharmacother. 2012 May; 13(7):927-38.
    View in: PubMed
    Score: 0.009
  120. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood. 2012 May 17; 119(20):4614-8.
    View in: PubMed
    Score: 0.009
  121. Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2012 Jun; 12(3):207-12.
    View in: PubMed
    Score: 0.009
  122. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood. 2012 Apr 12; 119(15):3403-12.
    View in: PubMed
    Score: 0.009
  123. Evolution of therapies for chronic myelogenous leukemia. Cancer J. 2011 Nov-Dec; 17(6):465-76.
    View in: PubMed
    Score: 0.009
  124. Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts. Leukemia. 2012 May; 26(5):883-92.
    View in: PubMed
    Score: 0.009
  125. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood. 2011 Nov 17; 118(20):5697-700.
    View in: PubMed
    Score: 0.009
  126. Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure. Clin Lymphoma Myeloma Leuk. 2011 Jun; 11 Suppl 1:S101-10.
    View in: PubMed
    Score: 0.009
  127. Mutant BCR-ABL clones in chronic myeloid leukemia. Haematologica. 2011 Mar; 96(3):347-9.
    View in: PubMed
    Score: 0.009
  128. Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy. Haematologica. 2011 Jun; 96(6):918-21.
    View in: PubMed
    Score: 0.009
  129. New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. Leuk Lymphoma. 2011 Feb; 52 Suppl 1:81-91.
    View in: PubMed
    Score: 0.009
  130. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011 Jan; 121(1):396-409.
    View in: PubMed
    Score: 0.009
  131. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer. 2011 May 01; 117(9):1800-11.
    View in: PubMed
    Score: 0.009
  132. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011 Jan 27; 117(4):1141-5.
    View in: PubMed
    Score: 0.009
  133. Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia. Expert Opin Pharmacother. 2010 Dec; 11(18):3065-72.
    View in: PubMed
    Score: 0.009
  134. Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications. Cancer. 2011 Feb 15; 117(4):688-97.
    View in: PubMed
    Score: 0.008
  135. Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays. Cancer Sci. 2010 Sep; 101(9):2005-10.
    View in: PubMed
    Score: 0.008
  136. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer. 2010 Aug 15; 116(16):3852-61.
    View in: PubMed
    Score: 0.008
  137. Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. Cancer. 2010 Aug 01; 116(15):3631-7.
    View in: PubMed
    Score: 0.008
  138. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia. 2010 Jul; 24(7):1299-301.
    View in: PubMed
    Score: 0.008
  139. Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. Cancer. 2010 Jun 01; 116(11):2665-72.
    View in: PubMed
    Score: 0.008
  140. Tyrosine kinase inhibitors: the first decade. Curr Hematol Malig Rep. 2010 Apr; 5(2):70-80.
    View in: PubMed
    Score: 0.008
  141. Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase. Cancer. 2010 Mar 15; 116(6):1419-30.
    View in: PubMed
    Score: 0.008
  142. Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer. 2009 Dec 01; 115(23):5382-93.
    View in: PubMed
    Score: 0.008
  143. Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood. 2009 Dec 17; 114(26):5271-8.
    View in: PubMed
    Score: 0.008
  144. Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. Leukemia. 2010 Jan; 24(1):6-12.
    View in: PubMed
    Score: 0.008
  145. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer. 2009 Sep 15; 115(18):4136-47.
    View in: PubMed
    Score: 0.008
  146. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood. 2009 Nov 12; 114(20):4361-8.
    View in: PubMed
    Score: 0.008
  147. Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. Cancer. 2009 Sep 01; 115(17):3935-43.
    View in: PubMed
    Score: 0.008
  148. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol. 2009 Sep 01; 27(25):4204-10.
    View in: PubMed
    Score: 0.008
  149. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer. 2009 Jun 01; 115(11):2482-90.
    View in: PubMed
    Score: 0.008
  150. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood. 2009 Jun 18; 113(25):6322-9.
    View in: PubMed
    Score: 0.008
  151. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer. 2008 Sep 01; 113(5):985-94.
    View in: PubMed
    Score: 0.007
  152. Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias. Expert Opin Investig Drugs. 2008 Jul; 17(7):1127-36.
    View in: PubMed
    Score: 0.007
  153. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov. 2007 Oct; 6(10):834-48.
    View in: PubMed
    Score: 0.007
  154. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest. 2007 Sep; 117(9):2408-21.
    View in: PubMed
    Score: 0.007
  155. Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors. Oncogene. 2008 Jan 31; 27(6):775-82.
    View in: PubMed
    Score: 0.007
  156. New approaches to the management of Philadelphia-chromosome-positive acute lymphocytic leukemia. Curr Hematol Malig Rep. 2007 Jul; 2(3):183-9.
    View in: PubMed
    Score: 0.007
  157. The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1. Leukemia. 2007 Jul; 21(7):1395-404.
    View in: PubMed
    Score: 0.007
  158. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias. Expert Opin Investig Drugs. 2007 May; 16(5):679-87.
    View in: PubMed
    Score: 0.007
  159. Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs? Oncology (Williston Park). 2007 May; 21(6):653-62; discussion 663-4, 667-8.
    View in: PubMed
    Score: 0.007
  160. Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia. Curr Hematol Malig Rep. 2007 May; 2(2):83-8.
    View in: PubMed
    Score: 0.007
  161. New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance. Semin Hematol. 2007 Jan; 44(1 Suppl 1):S25-31.
    View in: PubMed
    Score: 0.007
  162. Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib. Future Oncol. 2006 Dec; 2(6):655-65.
    View in: PubMed
    Score: 0.006
  163. Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer. 2006 Jun 15; 106(12):2645-51.
    View in: PubMed
    Score: 0.006
  164. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006 Jun 15; 354(24):2531-41.
    View in: PubMed
    Score: 0.006
  165. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006 Jun 15; 354(24):2542-51.
    View in: PubMed
    Score: 0.006
  166. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006 Sep 15; 108(6):1809-20.
    View in: PubMed
    Score: 0.006
  167. Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer. 2006 Jan 01; 106(1):120-7.
    View in: PubMed
    Score: 0.006
  168. Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia. Curr Mol Med. 2005 Nov; 5(7):615-23.
    View in: PubMed
    Score: 0.006
  169. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2005 Sep 15; 11(18):6615-24.
    View in: PubMed
    Score: 0.006
  170. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res. 2005 Jul 01; 11(13):4941-7.
    View in: PubMed
    Score: 0.006
  171. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood. 2004 Oct 01; 104(7):1979-88.
    View in: PubMed
    Score: 0.005
  172. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res. 2003 Oct; 27(10):893-7.
    View in: PubMed
    Score: 0.005
  173. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer. 2003 Apr 01; 97(7):1711-20.
    View in: PubMed
    Score: 0.005
  174. New agents in the treatment of acute lymphocytic leukaemia. Best Pract Res Clin Haematol. 2002 Dec; 15(4):771-90.
    View in: PubMed
    Score: 0.005
  175. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemother Pharmacol. 2003 Jan; 51(1):87-90.
    View in: PubMed
    Score: 0.005
  176. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. J Clin Oncol. 2000 Oct 15; 18(20):3513-21.
    View in: PubMed
    Score: 0.004
  177. Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance. Cancer. 1999 Sep 01; 86(5):805-13.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.